From biochemical markers to molecular endotypes of osteoarthritis: a review on validated biomarkers

Monica T. Hannani,Christian S. Thudium,Morten A. Karsdal,Christoph Ladel,Ali Mobasheri,Melanie Uebelhoer,Jonathan Larkin,Jaume Bacardit,André Struglics,Anne-Christine Bay-Jensen
DOI: https://doi.org/10.1080/14737159.2024.2315282
2024-02-16
Expert Review of Molecular Diagnostics
Abstract:Introduction Osteoarthritis (OA) affects over 500 million people worldwide. OA patients are symptomatically treated, and current therapies exhibit marginal efficacy and frequently carry safety-risks associated with chronic use. No disease-modifying therapies have been approved to date leaving surgical joint replacement as a last resort. To enable effective patient care and successful drug development there is an urgent need to uncover the pathobiological drivers of OA and how these translate into disease endotypes. Endotypes provide a more precise and mechanistic definition of disease subgroups than observable phenotypes, and a panel of tissue- and pathology-specific biochemical markers may uncover treatable endotypes of OA.
pathology
What problem does this paper attempt to address?